Wellbutrin, it is not a significant effect. Reboxetine, which is going to come out next year, also produces very a low frequency of weight gain because it's, essentially, a pure norepinephrine uptake inhibiting antidepressant medication. Therefore, it is essentially identical to Effexor or identical to an SSRI plus a noradregenically active drug. We do not use Meridia in combination with those other drugs because I really don't think Meridia is going to add benefit, but there is a potential for side effect interaction. I don't think it's going to be catastrophic under both circumstances, but I also don't think that Meridia is going to be particularly beneficial in that regard.
Severity is a relative indicator.
Generally speaking, a depressive episode is considered severe, first of all, if the patient has many, many symptoms of depression. Depressions of lesser severity are not trivial in that regard, but we would certainly consider that if a patient is having a major life impairment they would be considered a patient who is severely depressed. Under conditions in which patients receive significant treatment, there does not seem to be significant progress in severity of symptoms. The NIMH data collaborative data has indicated it. But in most of the earlier studies, looking at patients over time in an undertreated environment has shown that depressive symptoms do get worse.